Compare JF & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JF | GNTA |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | Italy |
| Employees | 30 | 13 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5M | 19.9M |
| IPO Year | N/A | N/A |
| Metric | JF | GNTA |
|---|---|---|
| Price | $1.02 | $0.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 42.0K |
| Earning Date | 04-24-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.89 | $0.55 |
| 52 Week High | $1.12 | $10.00 |
| Indicator | JF | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 40.11 |
| Support Level | $0.90 | $0.61 |
| Resistance Level | $1.09 | $0.76 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 61.77 | 33.33 |
J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.